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ABSTRACT 
Arterial medial calcification (AMC) has been associated with phenotypic changes in vascular smooth 
muscle cells (VSMCs) that reportedly makes them more osteoblast-like. Previous work has shown that 
ATP/UTP can inhibit AMC directly via P2 receptors and indirectly by NPP1-mediated hydrolysis to 
produce the mineralisation inhibitor, pyrophosphate (PPi). This study investigated the role of P2X 
receptors in the inhibitory effects of extracellular nucleotides on VSMC calcification.  We found that Bz-
ATP, α,β-meATP and β,γ-meATP, inhibited calcification by up to 100%.  Culture in a high phosphate 
medium (2mM) was associated with increased VSMC death and apoptosis; treatment with Bz-ATP, α,β-
meATP and β,γ-meATP reduced apoptosis to levels seen in non-calcifying cells.  Calcification was also 
associated with alterations in the protein levels of VSMC (e.g. SM22α, SMA) and osteoblast-associated 
(e.g. Runx2, osteopontin) markers; Bz-ATP, α,β-meATP and β,γ-meATP attenuated these changes in 
protein expression. Long-term culture with Bz-ATP, α,β-meATP and β,γ-meATP resulted in lower 
extracellular ATP levels and an increased rate of ATP breakdown.  P2X receptor antagonists failed to 
prevent the inhibitory effects of these analogues suggesting that they act via P2X receptor-independent 
mechanisms. In agreement, the breakdown products of α,β-meATP and β,γ-meATP (α,β-meADP and 
methylene diphosphonate, respectively) also dose dependently inhibited VSMC calcification.  
Furthermore, the actions of Bz-ATP, α,β-meATP and β,γ-meATP were unchanged in VSMCs isolated 
from NPP1 knockout mice, suggesting that the functional effects of these compounds do not involve  
NPP1-mediated generation of PPi.  Together, these results indicate that the inhibitory effects of ATP 
analogues on VSMC calcification and apoptosis in vitro may be mediated, at least in part, by 
mechanisms that are independent of purinergic signalling and PPi.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
INTRODUCTION 
Vascular calcification is a frequent consequence of chronic kidney disease, diabetes, atherosclerosis 
and ageing. It is the pathological deposition of calcium phosphate mineral, typically as hydroxyapatite, 
in the intimal and/or medial layers of the arteries and heart valves.  Arterial medial calcification (AMC) 
develops within the tunica media of blood vessels and is characterised by increased vessel stiffness 
and decreased blood flow [1].  Originally, it was thought that AMC was a passive process due to high 
serum levels of calcium and phosphate; however, it is now widely stated in the literature that AMC 
shares some outward similarities to physiological bone formation. In particular, development of AMC is 
characterised by a loss of calcification inhibitors (e.g. pyrophosphate (PPi), fetuin A, matrix gla protein), 
a gain of calcification inducers (e.g. alkaline phosphatase (TNAP)), and increased apoptosis [1,2].  
Vascular smooth muscle cells (VSMCs) are the major cell type driving AMC and when maintained in a 
calcifying environment (high calcium and/or phosphate) these cells undergo phenotypic changes to take 
on some limited osteoblast-like characteristics [3-7].  
ATP and related nucleotides (UTP, ADP, UDP) are important extracellular signalling molecules that act 
via purinergic P2 receptors to regulate cell proliferation, differentiation, survival and function in many 
tissues [8]. The P2 receptor family comprises seven P2X ion channels (P2X1-7) and eight P2Y G-
protein coupled receptors (P2Y1,2,4,6,11-14) [9,10].  The study of P2X receptor function has been aided by 
synthetic ATP analogues which act as receptor agonists with a degree of selectivity for the different 
subtypes.  These include Bz-ATP (P2X7 and, weakly, P2X1), α,β-meATP (most potent at P2X1 and 
P2X3, also P2X4) and β,γ-meATP (P2X1, weakly P2X2 and P2X3) [11]. The recent development of 
numerous selective P2X receptor antagonists has also aided in the study of these receptors. 
Whilst the role of purinergic signalling in the cardiovascular system has been well documented (see 
review [12]), the regulation of vascular calcification by extracellular nucleotides has been less well 
investigated [13].  To date most studies have reported protective effects with ATP and UTP being able 
to reduce AMC, valve calcification and intimal calcification [6,14-16].  However, the mechanisms 
underpinning these functional effects appear to vary between the different forms of calcification. For 
example, P2Y2 receptor mediated signalling has been shown to promote the survival of aortic valve 
interstitial cells as well as protect against aortic valve calcification [14] and arterial intimal calcification 
[15].  In contrast, whilst ATP and UTP can inhibit VSMC calcification by preventing apoptosis, these 
effects do not appear to be mediated via the P2Y2 receptor [6]. 
VSMCs, like many other cell types, release ATP constitutively [17,18].  Once released, extracellular 
nucleotides are rapidly hydrolysed by ecto-nucleotidases.  One important product of these breakdown 
reactions is PPi, a ubiquitous and potent physiochemical inhibitor of calcification [19].  PPi is generated 
from nucleotide triphosphates by ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs).  
VSMCs express high levels of NPP1 and the hydrolysis of locally released ATP by this enzyme is a 
major source of extracellular PPi [17,20]. Once generated, this PPi can then act locally to prevent VSMC 
calcification.  In agreement, we recently reported that the inhibitory effects of ATP/UTP on AMC are 
attenuated in VSMCs derived from NPP1 knockout mice [6]. This suggests that the actions of these 
extracellular nucleotides are mediated by both P2 receptor-dependent and independent mechanisms 
(i.e. hydrolysis to produce PPi).   
Although earlier work from our laboratory showed that the P2Y2 receptor did not mediate the effects of 
ATP and UTP on VSMC calcification [6], it was not defined whether any of the other P2 receptor 
subtypes were involved. The aim of this study was to determine which P2 receptor(s) mediates these 
functional effects.  Thus, the more selective ATP analogues, Bz-ATP, α,β-meATP and β,γ-meATP, were 
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used to investigate the role of the P2X receptors in the inhibition of VSMC calcification by extracellular 
nucleotides.  
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METHODS 
Reagents 
All tissue culture reagents were purchased from Life Technologies (Paisley, UK); unless mentioned, all 
chemicals were purchased from Sigma Aldrich (Poole, UK).  All P2X receptor antagonists were obtained 
from Tocris Bioscience (Bristol, UK) and all P2X receptor antibodies from Alomone Labs (Jerusalem, 
Israel).  All other antibodies were purchased from Abcam (Cambridge, UK). 
Animals 
Primary VSMCs were isolated from C57BL/6J, NPP1 knockout (Enpp1-/-) or NPP1 wildtype (Enpp1+/+) 
mice. Enpp1-/- and Enpp1+/+ VSMCs were isolated from animals on a 129Sv/TerJ background. The 
generation and characterisation of Enpp1-/- animals has previously been described [21]. Animals were 
bred from heterozygote (Enpp1+/-) breeding pairs due to the inability of homozygotes to breed.  All mice 
were housed under standard conditions with free access to food and water. All procedures complied 
with the UK animals (Scientific Procedures) Act 1986 and were reviewed and approved by the Royal 
Veterinary College Research Ethics Committee.  
Vascular smooth muscle cell (VSMC) calcification assay  
Primary VSMCs were isolated from aortas of 6-8 week old mice. After removal of the adventitia, the 
aorta was opened to expose the endothelial layer under a dissection microscope.  Tissues from 6-8 
animals were pooled and incubated with trypsin (0.25% w/v) for 10 minutes to remove any remaining 
adventitia and endothelium. Tissues were incubated overnight in alpha Minimum Essential Medium, 
supplemented with 10% foetal calf serum (FCS), 100U/ml penicillin, 100µg/ml streptomycin and 
0.25µg/ml amphotericin (complete mixture abbreviated to αMEM) before being digested with 425U/ml 
collagenase type II (Worthington Biomedical Corporation, Lakewood, USA) for 5 hours. Isolated VSMCs 
were expanded in T25 tissue culture flasks in a humidified atmosphere of 5% CO2-95% air at 37C until 
confluent. Following seeding into 24-well plates at a density of 2.5 x 104 cells/well, VSMCs were cultured 
in calcifying medium (αMEM + 2mM sodium phosphate) for up to 14 days, with half medium changes 
every 3 days.  Cells were treated with 1-100µM Bz-ATP, α,β-meATP or β,γ-meATP and, where 
appropriate, P2 receptor antagonists (0.1-10M), for the duration of the culture; fresh agonist/antagonist 
was added at each medium change.  The P2 receptor antagonists used were:  PPADS (non-selective), 
NF110 (P2X3), 5-BDBD/PSB-12062 (P2X4) and A740003/AZ10606120 (P2X7). The antagonists were 
used at concentrations previously shown to abolish the functional effects of Bz-ATP and α,β-meATP on 
bone mineralisation in long term cultures [22]. 
Determination of VSMC calcification 
Calcifying VSMCs were washed twice with phosphate buffered saline (PBS) and incubated with 0.6M 
HCl at room temperature for 24 hours.  Calcium content was measured colorimetrically by stable 
interaction with o-cresolphthalein using a commercially available kit (Calcium Colorimetric Assay, 
Sigma-Aldrich, Poole, UK) and corrected for total protein concentration using the Bradford assay 
(Sigma-Aldrich, Poole, UK).  Calcium deposition was visualised by alizarin red staining of VSMC cell 
layers as previously described [23]. 
Total RNA extraction and DNase treatment 
Calcifying VSMCs were cultured for 14 days before total RNA was extracted using TRIZOL reagent 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions.   Extracted RNA was treated with 
RNase-free DNase I (35U/ml) for 30 min at 37C. The reaction was terminated by heat inactivation at 
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65C for 10 min.  Total RNA was quantified spectrophotometrically by measuring absorbance at 260nM.   
RNA was stored at –80C until amplification by qRT-PCR. 
Quantitative real time polymerase chain reaction (qRT-PCR) 
VSMC RNA (50ng) was transcribed and amplified using the qPCRBIO SyGreen one-step qRT-PCR kit 
(PCR Biosystems, London, UK), which allows cDNA synthesis and PCR amplification to be carried out 
sequentially.  qRT-PCR was performed according to manufacturer’s instructions with initial cDNA 
synthesis (45°C for 10 min) and reverse transcriptase inactivation (95°C for 2 min) followed by 40 cycles 
of denaturation (95C for 5 sec) and detection (60°C for 30 sec). All reactions were carried out in 
triplicate using RNAs derived from 4 different cultures.  Data are presented as mRNA expression 
relative to P2Y2 receptor expression. Primers sequences (forward/reverse): β-actin, S: gcc ttc ctt cct 
ggg tat gg  /  AS: tcc gat tca act cat act gc; P2X1, S: tgt acg ggg aga aga acc tg / AS: tcc caa aca cct 
tga aga gg; P2X2, S: cgt ctt cat cgt gca gaa aa / AS: cac ttt gtg ttc cga cat gg; P2X3, S: tac caa gtc ggt 
ggt tgt ga / AS: cca ccc cac aaa gta gga ga; P2X4, S: gca ccc tcc acc atc tct aa / AS: aaa cct ctt gcc 
aga agc aa; P2X5, S: ggg ctt tct tct gtg acc tg / AS: gtt ggc ctc aac ctc aac at; P2X6, S: agc cat ggc ata 
aaa act gg / AS: gtg aag ttc ttg gcc tga gc; P2X7, S: ggc act gga gga aaa ttt ga / AS: tga gca agt caa 
tgc aca ca; P2Y1, S: agg aaa gct tcc agg agg ag / AS: cgt gtc tcc att ctg ctt ga; P2Y2, S: gtc agc agt gac 
gac tca aga c / AS: tca gag gat atc agc ccc ttt a; P2Y4, agg aag cag cag aac acc at / AS: caa gga gtc 
tgc act ggt ca; P2Y12, S: cct gtg cgt cag aga cta caa g / AS: gga ttt act gcg gat ctg aaa g.  
Western blotting 
Protein was extracted from control VSMCs and VSMCs treated with 25µM α,β-meATP, 10µM β,γ-
meATP or 100µM Bz-ATP for 7 and 14 days.  Cell layers were lysed in ice-cold radio 
immunoprecipitation (RIPA) lysis buffer (50mM Tris HCl pH 7.4, 150mM NaCl, 5mM EDTA, 0.1% SDS, 
1mM phenyl methyl sulfonyl fluoride (PMSF), 1mg/ml aprotinin, 1mM Na3VO4 and 2.5mg/ml deoxicolic 
acid).  Cell homogenates were sonicated for 5 min before use.  Protein concentrations from lysates 
were determined using the Bradford assay.  Prior to loading total protein, samples were denatured by 
incubating at 95C for 5 min in the presence of 5x reducing sample buffer (60 mM Tris-HCl pH 6.8, 25% 
glycerol, 2% SDS, 10% -mercaptoethanol and 0.1% bromophenol blue).  Protein samples (20g/lane) 
were loaded into SDS-PAGE (10%) gels and transferred onto a polyvinylidenifluoride (PVDF) 
membrane (Amersham, Buckinghamshire, UK) using a wet tank blotter (Bio-Rad, Watford, UK) at 150 
V for 1 hour.  Membranes were then blocked with 5% non-fat milk and incubated with β-actin (1:1000), 
P2X receptor (1:200), SM22α (1:500), Acta2 (1:200), Runx2 (1:500) or osteopontin (OPN, 1:200) 
antibodies overnight at 4oC.  Blots were incubated in horseradish peroxidase-conjugated secondary 
antibodies for 1 hour at room temperature.  A peroxidase detection system (Immobilon™ Western, 
Merck-Millipore, Watford UK) and ChemiDocTM XRS+ system (Bio-Rad, Watford, UK) was used for 
visualisation of the immunoreactivity.   
Cell number and viability assay   
VSMCs were cultured for 14 days in medium supplemented with Bz-ATP, α,β-meATP or β,γ-meATP  
(1-100µM); fresh nucleotide was added at each medium change. Cell number and viability were 
determined using the CytoTox 96® colorimetric cytotoxicity assay (Promega UK, Southampton UK), as 
described previously [22]. Cell supernatants were collected to determine medium LDH levels (cell 
viability).   To establish total cellular LDH levels, VSMCs were lysed with 1% Triton X-100 in water (lysis 
buffer, 15µl/ml of medium) for 1 hour. The LDH content of the supernatants and cell lysates were 
measured colorimetrically (490nm) according to the manufacturer’s instructions.  A standard curve for 
determination of cell numbers was constructed using cells seeded at 102 to 106/well. VSMC viability 
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(shown as percentage of dead cells) was calculated by expressing medium LDH as a percentage of the 
total cellular LDH. 
Quantification of apoptosis by flow cytometry 
VSMCs were cultured in control or calcification medium (± 1-100µM Bz-ATP, α,β-meATP, or β,γ-
meATP) for 7 days. Apoptosis was assessed via flow cytometry using an annexin V antibody conjugated 
to fluorescein (Life Technologies, Paisley, UK), as per manufacturer’s instructions. Briefly, VSMCs were 
detached using 0.25% trypsin and the resultant pellet washed in ice-cold PBS. This suspension was 
centrifuged and resuspended in 1X annexin-binding buffer (Life Technologies, Paisley, UK). A sample 
of this suspension was incubated with the annexin V antibody for 15 minutes, before analysis using a 
BD FACSCanto II Flow Cytometer (Becton, Dickinson and Company, Oxford, UK). Data were 
processed to calculate percentage apoptosis using Flowing Software (version 2.5.1) (Turku University, 
Finland). 
Determination of alkaline phosphatase (TNAP) activity 
VSMCs were cultured with 1-100µM Bz-ATP, α,β-meATP or β,γ-meATP for 14 days; fresh nucleotide 
was added at each medium change.  TNAP activity was measured in cell lysates using a colorimetric 
assay (Anaspec, CA, USA), as previously described [22].  TNAP activity was normalised to cell protein 
using the Bradford assay.     
Measurement of ATP release and breakdown  
VSMCs were cultured with Bz-ATP (100µM), α,β-meATP (25µM) or β,γ-meATP (10µM) for 14 days. On 
the day of assay cells were switched to serum-free DMEM (without Bz-ATP, α,β-meATP or β,γ-meATP) 
and left for 60 minutes to allow any ATP released during the medium exchange to be degraded.  After 
this time, samples were taken to measure basal ATP levels and cell viability.   ATP (1µM) was then 
added to each well and samples taken after a further 2, 5, 10, 30 and 60 minutes to assess rate of ATP 
breakdown. ATP levels were measured luminetrically using the luciferin-luciferase assay, as described 
previously [24].   
Measurement of Pyrophosphate (PPi) levels 
VSMCs were cultured until widespread calcification was evident before measurement of PPi levels.  
Culture medium was removed, cell layers washed and cells incubated in 10mM HEPES buffer 
containing 0.9% NaCl and 1% BSA, pH 7.4 for 1 hour.  Bz-ATP (100µM), α,β-meATP (25µM), β,γ-
meATP (10µM) or ATP (10-100µM)  were added to the HEPES buffer and samples collected at 15 
minutes after treatment.  PPi levels were measured using a fluorescent assay kit (Pyrophosphate Assay 
Kit, Abcam, Cambridge, UK); assays were performed according to the manufacturer’s instructions. 
Statistical analysis 
Data were analysed using GraphPad Prism 7 software (San Diego, CA).  Statistical comparisons were 
made using a T-test or a one-way analysis of variance (ANOVA) with a post-hoc Bonferroni correction 
for multiple comparisons.  Results shown are representative of experiments performed at least three 
times using cells obtained from different animal isolations. Each individual experiment comprised 4-12 
technical replicates. 
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RESULTS 
Expression of functional P2 receptors by calcifying VSMCs 
Calcifying VSMCs (day 14 of culture) express mRNA for all P2X receptors and some P2Y receptors 
(P2Y1, P2Y2, P2Y4, P2Y12) (Fig. 1A).  Western blot analysis of cell lysates after 7 and 14 days of culture 
revealed that calcifying VSMCs displayed protein expression of P2X3, P2X4, P2X5 and P2X7 receptors 
(Fig. 1B).  No protein expression of P2X1, P2X2 and P2X6 receptors was detected.  For all P2X 
receptors, positive controls using osteoblast protein were carried out to show the antibodies were 
functional.   
Inhibition of VSMC calcification by Bz-ATP, α,β-meATP and β,γ-meATP 
Bz-ATP (100µM) and α,β-meATP (≥25µM) inhibited VSMC calcification by up to 95% (Fig. 2A & 2B). 
β,γ-meATP was the most potent of the ATP-analogues tested as it completely prevented all calcification 
at concentrations of ≥10µM  (Fig. 2C).  Comparatively, ATP (≥10µM) decreased VSMC calcification by 
up to 80% [6]. Representative phase contrast images of alizarin red stained cell layers in Fig. 2D show 
normal phosphate-induced VSMC calcification and the inhibitory actions of Bz-ATP (100µM), α,β-
meATP (25µM) and β,γ-meATP (10µM). 
Bz-ATP, α,β-meATP and β,γ-meATP increase VSMC viability and decrease apoptosis 
In calcifying VSMCs, treatment with Bz-ATP, α,β-meATP and β,γ-meATP (≥1µM) decreased the 
percentage of dead cells present by up to 72% (Fig. 3A-3C). However, there was no overall effect on 
total cell number (Fig. 3D-3F). Apoptosis was increased up to 2.1-fold in calcifying VSMCs compared 
to control VSMCs (Fig. 3G-3I).  Treatment with 100µM Bz-ATP and β,γ-meATP (≥10µM) decreased the 
level of apoptosis seen in calcifying cells to a level similar to that in control VSMCs (Fig. 3G & 3I).  
Culture with α,β-meATP (50µM) reduced the amount of apoptosis in calcifying cells by 25% (Fig. 3H).   
The effect of Bz-ATP, α,β-meATP and β,γ-meATP on calcification-induced changes in VSMC 
protein expression 
The effect of Bz-ATP (100µM), α,β-meATP (25µM) and β,γ-meATP (10µM) on the protein expression 
of VSMC and osteoblast markers was investigated using western blotting (Fig. 4). VSMC calcification 
was associated with lower protein levels of SM22-α and Acta2 at day 14 compared to day 7; treatment 
with Bz-ATP, α,β-meATP or β,γ-meATP appeared to prevent this reduction.  Little or no OPN or Runx2 
expression was detected in VSMCs at day 7 of culture; however, limited protein expression was evident 
by day 14.  Protein levels of Runx2 and OPN appeared to be slightly reduced in VSMCs cultured with 
Bz-ATP, α,β-meATP and β,γ-meATP.  
The inhibitory effects of Bz-ATP, α,β-meATP and β,γ-meATP on VSMC calcification are not 
mediated by P2X receptors 
A combination of selective and non-selective P2X receptor antagonists were then tested to identify 
which receptor subtype(s) mediates the effects of Bz-ATP, α,β-meATP and β,γ-meATP on VSMC 
calcification.  PPADs (a non-selective P2 receptor antagonist) did not prevent the inhibitory effects of 
Bz-ATP, α,β-meATP or β,γ-meATP (Fig 5A-5C).  Of the ATP-analogues tested, only α,β-meATP and 
β,γ-meATP  activate the P2X3 receptor; however, receptor inhibition with NF110 had no effect on the 
actions of either compound (Fig. 5D & 5E).  Selective antagonists for the P2X4 (5-BDBBD, PSB-12062) 
and P2X7 (A740003, AZ10606120) receptors also failed to prevent the inhibitory effects of α,β-meATP 
and Bz-ATP, respectively (Fig. 5F-5I).  Due to the extended nature of VSMC cultures, selective P2X 
receptor antagonists were not used at concentrations above 10M because they resulted in obvious 
cell death. 
9 
 
Increased TNAP activity in VSMCs treated with Bz-ATP, α,β-meATP and β,γ-meATP 
Treatment with Bz-ATP (100µM), α,β-meATP (≥25µM) and β,γ-meATP (≥10µM) increased TNAP 
activity up to 5.5-fold, 2.2-fold and 5.9-fold, respectively (Fig. 6A-6C). The concentrations at which 
TNAP activity was increased corresponded to the levels at which calcification was significantly inhibited 
(Fig. 2).  
The effect of Bz-ATP, α,β-meATP and β,γ-meATP on ATP release and breakdown 
High concentrations of α,β-meATP and β,γ-meATP have been shown to inhibit ecto-nucleotidases and 
therefore slow ATP breakdown [17,25]. Basal extracellular ATP levels were 70% and 45% lower in 
VSMCs cultured with α,β-meATP and β,γ-meATP, respectively (Fig. 6D).  ATP levels were unchanged 
in Bz-ATP-treated VSMCs (Fig. 6D). The breakdown of exogenously added ATP was faster in VSMCs 
cultured with Bz-ATP (Fig. 6E), α,β-meATP (Fig. 6F) and β,γ-meATP (Fig. 6G).  The cells treated with 
α,β-meATP showed the largest difference in the rate of ATP breakdown. To avoid any potential 
confounding effects of the ATP analogues on the luciferin-luciferase reaction, all ATP measurements 
were performed using culture medium that did not contain Bz-ATP, α,β-meATP or β,γ-meATP. 
The inhibitory effects of Bz-ATP, α,β-meATP and β,γ-meATP on VSMC calcification are not 
mediated by breakdown to produce PPi  
Enpp1-/- VSMCs were used to determine if any indirect actions involving NPP1 contributed to the effects 
of ATP-analogues.  Deletion of NPP1 did not prevent or reduce the inhibitory actions of Bz-ATP, α,β-
meATP or β,γ-meATP (Fig. 7A-7C).  Comparatively, the effects of ATP/UTP on VSMC calcification 
were attenuated in Enpp1-/- cells, suggesting that some of the inhibitory actions of these nucleotides 
are due to NPP1-mediated breakdown to produce PPi [6]. Addition of exogenous ATP (≥10µM) to VSMC 
cultures increased extracellular PPi levels by up to 4µM within 15 minutes of treatment (Fig. 7D).Bz-
ATP (100µM), α,β-meATP (25µM) and β,γ-meATP (10µM) only increased extracellular PPi levels by a 
small amount (≤0.7µM) (Fig. 7D). 
Breakdown products of α,β-meATP and β,-meATP also inhibit VSMC calcification 
The breakdown product of α,β-meATP, α,β-meADP, dose-dependently (≥10M) inhibited VSMC 
calcification by up to 95% (Fig. 8A). Methylene diphosphonate (≥10M), which is formed by the 
hydrolysis of β,γ-meATP, reduced VSMC  calcification by up to 80% (Fig. 8B).    
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DISCUSSION 
 
This study found that the synthetic ATP-analogues and P2X receptor agonists, Bz-ATP, α,β-meATP 
and β,γ-meATP, all inhibited VSMC calcification in vitro.  These actions appear to be mediated, at least 
in part, by preventing apoptosis and reducing calcification-induced phenotypic changes in the VSMCs. 
Despite pharmacological studies using both non-specific and selective P2X receptor antagonists, this 
investigation could not attribute these functional effects to activation of a particular P2X receptor 
subtype(s). Furthermore, the effects of these ATP analogues did not involve NPP1-mediated generation 
of PPi and the breakdown products of α,β-meATP and β,γ-meATP (α,β-meADP and methylene 
diphosphonate, respectively) also inhibited VSMC calcification. Taken together, these findings suggest 
that these compounds may be acting via mechanisms that are independent of both P2X receptor 
activation and NPP1-mediated hydrolysis to prevent VSMC calcification.  
Accumulating evidence shows that extracellular nucleotides are protective against the different forms 
of vascular calcification [6,14-16].  However, the P2 receptor subtypes which mediate these effects 
appear to vary; for example, the inhibition of valve and intimal calcification is thought to involve P2Y2 
receptor activation [14,15].  In contrast, our previous work showed that the effects of ATP and UTP on 
VSMC calcification were not mediated via the P2Y2 receptor [6].  Since ATP is the universal P2 receptor 
agonist, this study investigated whether P2X receptor signalling contributes to the inhibitory effects of 
ATP on calcification. Like endogenous extracellular nucleotides, we found that Bz-ATP, α,β-meATP 
and β,γ-meATP also reduce VSMC calcification in vitro, with β,γ-meATP being the most potent.   
VSMCs expressed mRNA for each P2X receptor but protein was only detected for the P2X3, P2X4, 
P2X5 and P2X7 receptors.  Bz-ATP, α,β-meATP and β,γ-meATP each display a degree of selectivity 
for the different P2X receptors and therefore our initial findings suggested involvement of the P2X3, 
P2X4 and/or P2X7 receptor subtypes.  Subsequent pharmacological analysis showed that selective 
antagonists for the these receptors did not attenuate any of the actions of Bz-ATP, α,β-meATP and β,γ-
meATP on VSMC calcification. A non-selective P2 receptor antagonist (PPADS) was also without effect.  
This failure to block the actions of Bz-ATP, α,β-meATP and β,γ-meATP pharmacologically suggests 
that these compounds are acting via P2X receptor-independent mechanisms to elicit their functional 
effects on calcification, apoptosis and gene expression.  However, further work using knockout or 
knockdown approaches would be necessary to fully exclude involvement of P2X receptors. 
Earlier work has shown that a calcifying environment can trigger VSMC apoptosis [2].  This increased 
apoptosis can then contribute to further development of AMC since the apoptotic bodies can act as a 
nucleation site for the formation of hydroxyapatite crystals [2].  Similar to endogenous extracellular 
nucleotides [6], Bz-ATP, α,β-meATP and β,γ-meATP act in a protective manner by decreasing VSMC 
apoptosis to levels similar to that seen in non-calcifying cells. Fewer apoptotic bodies would result in 
less sites where hydroxyapatite formation can be initiated, thus contributing to the reduced calcification 
observed in treated VSMCs. 
AMC is also associated with phenotypic changes that result in reduced expression of VSMC marker 
genes and increased expression of osteoblast-associated genes [1].  In agreement, we found that the 
development of calcification was associated with decreased Sm22α and Acta2 protein expression and 
small increases in Runx2 and OPN protein expression. Treatment with Bz-ATP, α,β-meATP and β,γ-
meATP attenuated these calcification-induced changes in gene expression. This suggests that these 
compounds can modulate the phenotypic alterations that occur in VSMCs when in a calcifying 
environment.  It is unclear from the present study whether these actions are a direct consequence of 
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Bz-ATP, α,β-meATP and β,γ-meATP-induced signalling or a secondary consequence of the reduced 
apoptosis/calcification.  However, given that no P2X receptor subtype was attributed to the functional 
effects of these compounds, the latter seems more plausible. 
The metabolism of extracellular nucleotides is complex and involves numerous different enzymes with 
overlapping specificities [26].  Previous work has shown that β,γ-meATP and α,β-meATP (≥30µM 
although 300M is more commonly used) can inhibit ecto-nucleotidase (NTPdases and NPPs) activity 
which slows nucleotide metabolism and leads to ATP accumulation  [17,25,27].  Since ATP inhibits 
VSMC calcification [6,16], we investigated whether α,β-meATP, β,γ-meATP and Bz-ATP were acting 
indirectly via increased ATP levels. We found that extracellular ATP levels were in fact lower in VSMCs 
cultured long term with α,β-meATP and β,γ-meATP.  Furthermore, the breakdown of exogenously 
added ATP was faster in VSMCs that had been cultured long term with these compounds.  This 
suggests that α,β-meATP and β,γ-meATP are not inhibiting VSMC ecto-nucleotidase activity and may 
even be increasing enzyme activity or expression. The concentrations of α,β-meATP and β,γ-meATP 
studied here were, at 25µM and 10µM, respectively, lower than the levels at which enzyme inhibition 
has been reported [17,25].  Nonetheless, at these concentrations, these compounds reduced VSMC 
calcification by >85%. If decreased ecto-nucleotidase activity and the resultant ATP accumulation were 
contributing to the functional effects of these compounds it would be expected to be evident using these 
concentrations.   
NPP1 deletion leads to decreased extracellular PPi levels and the development of vascular calcification 
[28].  We have shown that the inhibitory effects of ATP and UTP on VSMC calcification are partially 
mediated indirectly via the actions of NPP1 to generate PPi [6]. Studies here using Enpp1-/- VSMCs 
showed that deletion of NPP1 had no effect on the inhibitory actions of α,β-meATP, β,γ-meATP or Bz-
ATP. Furthermore, treatment with Bz-ATP, α,β-meATP or β,γ-meATP only lead to marginal increases 
in extracellular PPi levels.  Taken together, these data suggest that these analogues are not hydrolysed 
by NPP1 to produce significant amounts of PPi.    
TNAP is a crucial enzyme in bone mineralisation and increased expression and activity has been 
associated with promoting the development of AMC [3,29].  The inhibition of bone mineralisation by 
ATP, UTP and ATP-analogues is in part mediated by decreased TNAP expression and activity [22,30].  
Interestingly, ATP and UTP, at levels which inhibit VSMC calcification, promote TNAP activity in 
calcifying VSMCs [6].  This study observed a similar stimulatory effect in VSMCs cultured with Bz-ATP, 
α,β-meATP and β,γ-meATP. The reason for this counter-intuitive increase in activity remains to be 
determined but, given that these compounds can modulate the activity of other ecto-nucleotidases 
[17,25,27], their effects could reflect direct interactions with the TNAP enzyme.  However, the basal 
TNAP activity in calcifying mouse VSMCs in vitro is low (being approximately 100-fold lower than 
mineralising osteoblasts) and calcification cannot be induced using low, physiologically relevant levels 
of the TNAP substrate, β-glycerophosphate (≤2mM) [6]. Therefore, the relative importance of this 
enzyme in ATP metabolism and driving calcification in this experimental model of AMC remains unclear.  
Our finding that Bz-ATP, α,β-meATP and β,γ-meATP do not appear to act directly via P2X receptors or 
indirectly via altered ecto-nucleotidase activity raises the question of their exact mechanism of action. 
Whilst historically considered to be relatively non-hydrolysable, it is now known that these ATP 
analogues can be metabolised to some extent [17,31].  Bz-ATP can be sequentially broken down to 
produce Bz-adenosine, whilst α,β-meATP can produce α,β-meADP [31].  β,γ-meATP can be hydrolysed 
to produce methylene diphosphonate, a bisphosphonate-like compound.  Bisphosphonates adhere 
strongly to mineralised matrix and have been shown to inhibit both vascular calcification [16,32-34] and 
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bone mineralisation [35,36]. This study found that both methylene diphosphonate and α,β-meADP 
blocked VSMC calcification at a similar potency to the parent compounds.  Bz-adenosine could not be 
commercially obtained and so it was not possible to determine whether this molecule mediated the 
functional effects of Bz-ATP.  Taken together these findings suggest that some of the actions of β,γ-
meATP and α,β-meATP are mediated indirectly via these breakdown products. However, since 
previous work has also shown that these ATP-analogues have some weak agonist activity at P2Y 
receptors [37], involvement of one of these receptors (except the P2Y2 receptor) cannot be discounted.  
This study provides clear evidence that ATP-analogues can reduce VSMC calcification and apoptosis 
and prevent changes in gene expression in vitro.  However, it also indicates that the P2X receptors are 
not involved in these actions. Instead our findings suggest that some of the functional effects observed 
are mediated indirectly via compounds generated during hydrolysis. 
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FIGURE LEGENDS 
 
Figure 1.  Expression of P2 receptors by calcifying VSMCs 
(A)  Calcifying VSMCs express mRNA for all P2X receptors and some of the P2Y receptors.  Results 
are shown as mRNA expression relative to P2Y2 receptor expression (dotted line).  Data are presented 
as box and whisker plots (min-to-max values, n = 5 RNA sets, * = p<0.05, ** = p<0.01). (B) Western 
blot analysis shows that calcifying VSMCs expression protein for the P2X3, P2X4, P2X5 and P2X7 
receptors; protein for the P2X1, P2X2 and P2X6 receptors was not detected. The positive control (+ve) 
was protein isolated from mature osteoblasts.  
Figure 2. Inhibition of VSMC calcification by Bz-ATP, α,β-meATP and β,γ-meATP 
Treatment with (A) Bz-ATP (100µM) and (B) α,β-meATP (≥25µM) reduced VSMC calcification by up to 
95%.  (C) β,γ-meATP (≥10µM) completely prevented VSMC calcification.  Data are presented as box 
and whisker plots (min-to-max values, n = 6 replicate wells, *** = p<0.001) and are representative of an 
experiment performed at least three times.  (D) Representative phase contrast images of alizarin red 
stained cell layers show the inhibitory effects of Bz-ATP, α,β-meATP and β,γ-meATP (regions of 
calcification highlighted by the arrows). Scale bar = 100µm. 
Figure 3.  The effect of Bz-ATP, α,β-meATP and β,γ-meATP on VSMC viability and apoptosis 
Treatment with (A) Bz-ATP, (B) α,β-meATP and (C) β,γ-meATP (≥1µM) reduced the percentage of 
dead cells present by up to 72%.  There was no effect on total cell number in (D) BzATP, (E) α,β-meATP 
and (F) β,γ-meATP treated VSMCs. (G) Bz-ATP reduced the level of apoptosis in calcifying VSMCs to 
a level similar to control cells.  (H) α,β-meATP (50µM) decreased VSMC apoptosis by 25%.  (I) β,γ-
meATP (≥10µM) prevented the VSMC apoptosis induced by a calcifying environment. Data are 
presented as box and whisker plots (min-to-max values, n = 4-6 replicate wells, * = p<0.05, *** = 
p<0.001) and are representative of an experiment performed at least three times.  
Figure 4. The effect of Bz-ATP, α,β-meATP and β,γ-meATP on calcification-induced changes in 
protein expression 
Western blot analysis showed calcification was associated with reduced protein levels of SM22-α, and 
Acta2 whilst Runx2 and OPN protein levels were increased. Bz-ATP, α,β-meATP and β,γ-meATP 
appeared to attenuate the calcification-associated alterations in gene expression in VSMCs after 14 
days of culture. Blots are representative of 3 experiments with similar results. 
Figure 5.  P2X receptor antagonists do not prevent the actions of Bz-ATP, α,β-meATP and β,γ-
meATP on VSMC calcification 
(A-C) The non-selective P2 receptor antagonist, PPADS, did not prevent the inhibitory effects of Bz-
ATP, α,β-meATP and β,γ-meATP.  (D-E) NF110, a selective P2X3 antagonist, (F-G) P2X4 receptor 
antagonists and (H-I) P2X7 receptor antagonists were also without effect. Data are presented as box 
and whisker plots (min-to-max values, n = 6 replicate wells, *** = p<0.001) and are representative of an 
experiment performed at least three times.  
Figure 6. The effect of Bz-ATP, α,β-meATP and β,γ-meATP on TNAP activity and ATP release 
and breakdown. 
(A) Bz-ATP, (B) α,β-meATP and (C) β,γ-meATP (≥10µM) increased VSMC TNAP activity by up to 5.9-
fold.  (D) Basal extracellular ATP levels were 70% and 45% lower in VSMCs cultured for 14 days with 
α,β-meATP (25µM) and β,γ-meATP (10µM), respectively.  Bz-ATP did not affect basal ATP levels. The 
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breakdown of exogenously added ATP was faster in VSMCs-treated with (E) Bz-ATP, (F) α,β-meATP 
and (G) β,γ-meATP. Data are presented as box and whisker plots (min-to-max values, n = 6 replicate 
wells) or means ± SEM (n = 6-12 replicate wells, * = p<0.05, ** = p<0.01, *** = p<0.001) and are 
representative of an experiment performed at least three times.  
Figure 7: The effects of Bz-ATP, α,β-meATP and β,γ-meATP are not mediated indirectly via NPP1 
The effects of (A) Bz-ATP, (B) α,β-meATP and (C) β,γ-meATP on VSMC calcification were not 
prevented or reduced by deletion of NPP1. (D) Treatment with ATP increased extracellular PPi levels 
by up to 4µM; Bz-ATP, α,β-meATP and β,γ-meATP increased PPi levels by ≤0.7µM.   Data are 
presented as box and whisker plots (min-to-max values, n = 6 replicate wells, *** = p<0.001) and are 
representative of an experiment performed at least three times.  
Figure 8. Breakdown products of α,β-meATP and β,γ-meATP also inhibit VSMC calcification 
(A) α,β-meADP (≥10M) and (B) methylene diphosphonate (≥10M) inhibit VSMC calcification by up 
to 95% and 80%, respectively. Data are presented as box and whisker plots (min-to-max values, n = 6 
replicate wells, *** = p<0.001) and are representative of an experiment performed at least three times.  
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